Barner Goes Out On A High As Boehringer Ingelheim Returns To Growth
This article was originally published in Scrip
Professor Dr Andreas Barner, the outgoing chief of Boehringer Ingelheim, was able to report a return to growth for the family-owned German company in 2015 at his final annual conference. The group was boosted by diabetes sales under its partnership with Eli Lilly & Co - as well as by the strength of the dollar. The company reports in euros but books nearly 40% of its sales in the US. With currency effects stripped out, the sales were up by a more modest 4.1% versus the 11.1% as reported.
You may also be interested in...
Portola plans to resubmit the crucial BLA for its anticoagulant reversal agent AndexXa 'in the second quarter of 2017' after its unexpected August CRL. An approval would shore up the commercial success of Xarelto and Eliquis. Meanwhile, it has filed an NDA for its own Factor Xa inhibitor, betrixaban.
A wave of data to support use of novel anticoagulants in real-world settings was presented at the European Society of Cardiology Congress, but the question is whether this will alter the course of the market still dominated by warfarin and trailed by J&J/Bayer's Xarelto.
Company had wanted accelerated approval for the antidote for all Factor Xa inhibitors, but will now focus the reversal agent on the two drugs commanding the largest markets – Bristol/Pfizer's Eliquis and J&J/Bayer's Xarelto.